Literature DB >> 10585581

Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma.

T Katoh1, R Boissy, N Nagata, K Kitagawa, Y Kuroda, H Itoh, T Kawamoto, D A Bell.   

Abstract

The polymorphic arylamine N-acetyltransferases (NAT1 and NAT2) have been implicated in increased susceptibility to certain malignancies. We analyzed genetic polymorphisms in both the NAT1 and NAT2 genes among 140 gastric adenocarcinoma patients, 103 colorectal adenocarcinoma patients and 122 healthy controls from Japan. The frequency of the specific genotype NAT1*10 allele, which contains a variant polyadenylation signal, was higher among all gastric adenocarcinoma cases, but this increase did not reach statistical significance. After grouping according to tumor differentiation of gastric adenocarcinoma patients, NAT1 polymorphism was a risk factor among the well-differentiated type of tumors (OR = 3.03, 95% CI 1. 08-8.46). Stratifying by smoking status, we found that the OR for heavy smokers with the NAT1*10 allele was 2.97 (95% CI 1.23-7.14). When the combined risk of NAT1*10 allele from smoking and tumor differentiation was calculated, we found that the risk of the NAT1*10 allele with heavy smoking was increased among the well - differentiated type of gastric adenocarcinoma (OR = 4.24, 95% CI 0. 87-20.6). The NAT1*10 genotype was not a significant risk factor in colorectal adenocarcinoma. No statistically significant differences were observed in the frequency of NAT2 rapid acetylation genotype in gastric (91.4%) or colorectal (95.2%) adenocarcinoma patients when compared with the control population (94.3%). Our results suggest the NAT1*10 allele may be an important genetic determinant of the well-differentiated type of gastric adenocarcinoma, which may be induced by smoking. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10585581     DOI: 10.1002/(sici)1097-0215(20000101)85:1<46::aid-ijc8>3.0.co;2-0

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  N-Acetyltransferase (NAT) 2 acetylator status and age of tumour onset in patients with sporadic and familial, microsatellite stable (MSS) colorectal cancer.

Authors:  Steffen Pistorius; Heike Goergens; Christoph Engel; Jens Plaschke; Stefan Krueger; Ruth Hoehl; Hans-Detlev Saeger; Hans K Schackert
Journal:  Int J Colorectal Dis       Date:  2006-08-02       Impact factor: 2.571

2.  A comparison of approaches for association studies of polymorphisms and colorectal cancer risk.

Authors:  S D Ramsey; R S Holmes; C L McDermott; D K Blough; K L Petrin; E M Poole; C M Ulrich
Journal:  Colorectal Dis       Date:  2012-09       Impact factor: 3.788

3.  Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.

Authors:  Tawanda Gumbo; Arnold Louie; Weiguo Liu; David Brown; Paul G Ambrose; Sujata M Bhavnani; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

Review 4.  Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms.

Authors:  Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Tsutomu Nishida; Masato Komori; Masakazu Yasumaru; Shuji Ishii; Yoshiaki Sasayama; Sunao Kawano; Norio Hayashi
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

5.  Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis.

Authors:  Youyang Zheng; Yong Li; Yaoshu Teng; Zhen Zhang; Xiaolin Cao
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

6.  N-acetyltransferase 2 status and gastric cancer risk: a meta-analysis.

Authors:  Jian Yu; Yue Deng; Jian-Ping Chen
Journal:  Tumour Biol       Date:  2014-04-15

7.  N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer.

Authors:  Semra Demokan; Yusufhan Suoglu; Mustafa Gözeler; Deniz Demir; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2009-11-08       Impact factor: 2.316

8.  NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations.

Authors:  Mansour S Al-Moundhri; Mohamed Al-Kindi; Maryam Al-Nabhani; Bassim Al-Bahrani; Ikram A Burney; Ali Al-Madhani; Shyam S Ganguly; Misbah Tanira
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

9.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15

10.  Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan.

Authors:  Minatsu Kobayashi; Tetsuya Otani; Motoki Iwasaki; Shusuke Natsukawa; Kozo Shaura; Yoichi Koizumi; Yoshio Kasuga; Hiromi Sakamoto; Teruhiko Yoshida; Shoichiro Tsugane
Journal:  Gastric Cancer       Date:  2010-01-05       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.